| Dr Alan R Burningham, MD | |
|
1003 Providence Dr, Ste 210, Newberg, OR 97132-7523 | |
| (503) 537-9000 | |
| (503) 537-5955 |
| Full Name | Dr Alan R Burningham |
|---|---|
| Gender | Male |
| Speciality | Otolaryngology |
| Experience | 24 Years |
| Location | 1003 Providence Dr, Newberg, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1578669487 | NPI | - | NPPES |
| 278331 | Medicaid | OR | |
| P01054230 | Other | OR | RR MEDICARE (PH&S)-PMG |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Y00000X | Otolaryngology | MD26532 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Providence Newberg Medical Center | Newberg, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Providence Health And Services Oregon | 0648183608 | 1328 |
News Archive
The Coalition for Pulmonary Fibrosis announced to more than 128,000 patients news that the first drug for the treatment of the deadly lung disease Pulmonary Fibrosis has passed a major hurdle in the European regulatory process and is likely to be approved in all 27 member countries of the European Union.
The lack of sexual activity and function among older adults is linked to poorer health outcomes, including cancer, coronary heart disease (CHD), and fair or poor self-rated health, a new sexual science study found.
Pfenex Inc., a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's LUCENTIS (ranibizumab injection).
As part of its expanded coverage of the XVI International AIDS Conference, held through Aug. 18 in Toronto, the Kaiser Daily HIV/AIDS Report will feature studies and initiatives released during the conference.
In other news, Partners HealthCare hopes to replace its patchwork approach to electronic health records with a single commercial system.
› Verified 3 days ago
| Entity Name | Providence Health & Services Oregon |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023488343 PECOS PAC ID: 0648183608 Enrollment ID: O20031106000652 |
News Archive
The Coalition for Pulmonary Fibrosis announced to more than 128,000 patients news that the first drug for the treatment of the deadly lung disease Pulmonary Fibrosis has passed a major hurdle in the European regulatory process and is likely to be approved in all 27 member countries of the European Union.
The lack of sexual activity and function among older adults is linked to poorer health outcomes, including cancer, coronary heart disease (CHD), and fair or poor self-rated health, a new sexual science study found.
Pfenex Inc., a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's LUCENTIS (ranibizumab injection).
As part of its expanded coverage of the XVI International AIDS Conference, held through Aug. 18 in Toronto, the Kaiser Daily HIV/AIDS Report will feature studies and initiatives released during the conference.
In other news, Partners HealthCare hopes to replace its patchwork approach to electronic health records with a single commercial system.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Alan R Burningham, MD Po Box 3158, Portland, OR 97208-3158 Ph: (503) 215-6494 | Dr Alan R Burningham, MD 1003 Providence Dr, Ste 210, Newberg, OR 97132-7523 Ph: (503) 537-9000 |
News Archive
The Coalition for Pulmonary Fibrosis announced to more than 128,000 patients news that the first drug for the treatment of the deadly lung disease Pulmonary Fibrosis has passed a major hurdle in the European regulatory process and is likely to be approved in all 27 member countries of the European Union.
The lack of sexual activity and function among older adults is linked to poorer health outcomes, including cancer, coronary heart disease (CHD), and fair or poor self-rated health, a new sexual science study found.
Pfenex Inc., a clinical-stage biotechnology company engaged in the development of biosimilar therapeutics, and Hospira, Inc., the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars, today announced that the companies have entered into an agreement to exclusively develop and commercialize for worldwide sales PF582, Pfenex's biosimilar candidate to Genentech's LUCENTIS (ranibizumab injection).
As part of its expanded coverage of the XVI International AIDS Conference, held through Aug. 18 in Toronto, the Kaiser Daily HIV/AIDS Report will feature studies and initiatives released during the conference.
In other news, Partners HealthCare hopes to replace its patchwork approach to electronic health records with a single commercial system.
› Verified 3 days ago
Matthew H Brookes, D.O. Otolaryngology Medicare: Accepting Medicare Assignments Practice Location: 1003 N Providence Dr Ste 210, Newberg, OR 97132 Phone: 503-537-5620 |